Search

Displaying results 3351 - 3360 of 9670 in total
  1. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.

  2. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

    Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  3. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. … It contains 6 N-linked oligosaccharide modification sites.

  4. Drug

    Mosedipimod

    go.drugbank.com/drugs/DB12592
    Investigational

    Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

  5. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.

  6. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.

    Products: IOBENGUANO [131 I] GE HEALTHCARE T
  7. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  8. Drug

    Technetium Tc-99m medronate

    go.drugbank.com/drugs/DB09138
    ApprovedInvestigational

    It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate.

  9. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin E immune FAB2 (equine), BOTULINUM NEUROTOXIN E IMMUNE FAB2, EQUINE
  10. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.